论文部分内容阅读
近年来，耐药结核患者逐渐增多，结核病治疗面临严峻挑战，新型抗结核药物研发愈加迫切，倍受关注。其中利福霉素类及其衍生物、氟喹诺酮类、新型大环内脂类等到中成药及其他药物已进入临床试验。该文就这些新型药物的作用机制、试验结果、临床疗效进行总结，尤其对利福布丁、莫西沙星、PA-824、TMC-207、利奈唑胺及PNU-100480进行重点介绍，以期为临床医师治疗结核病提供参考。“,”The patients with drug-resistant TB in recent years are gradually increasing,tuberculosis treat-ment facing serious challenges,new anti-TB drugs research and development becomes more and more urgent and attention,The rifampicin mildew element class and its derivatives,fluoroquinolones, novel macrocyclic lipid until the Chinese patent drugs and other drugs have entered clinical trials .Here is to make a review of the mechanism of these novel agents,test results and clinical efficacy, especially for rifabutin,moxifloxacin, PA-824,TMC-207,linezolid and PNU-100480 introduced,in order for clinical treatment of tuberculosis and provide a reference.